ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Insights from 2023 ASCO® Annual Meeting

S. O'Brien, C. Coombs

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Fixed-Duration Treatment in CLL: Current Considerations

UCI Health

E. Brem

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Tazemetostat in R/R FL: Impact of EZH2 Mutational Status on PFS

Bruce D. Cheson